化疗与程序性细胞死亡蛋白 1（PD-1）免疫检查点阻断（ICB）的联合应用已在多种恶性肿瘤中显示出显著的抗肿瘤疗效。这种治疗协同作用的一个关键机制在于，化疗能消除快速增殖的肿瘤细胞并释放肿瘤抗原，从而激活肿瘤特异性 CD8+T（TTST）细胞，而 ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients. This is an ASCO Meeting ...

Nigeria on Wednesday launched its first clinical trial using immunotherapy to treat colorectal cancer, a move doctors say ...

Schlesinger: For advanced cSCC, immunotherapy has been a game-changer. The first immunotherapy drugs approved in the space were PD-1 inhibitors such as cemiplimab (Libtayo; Regeneron) and ...

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not. In a ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...